

# Cleo Anastassopoulou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1276941/publications.pdf>

Version: 2024-02-01

58  
papers

2,055  
citations

331259

21  
h-index

276539

41  
g-index

62  
all docs

62  
docs citations

62  
times ranked

3124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Data-based analysis, modelling and forecasting of the COVID-19 outbreak. PLoS ONE, 2020, 15, e0230405.	1.1	657
2	Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Human Genomics, 2020, 14, 40.	1.4	121
3	Effect of recent thymic emigrants on progression of HIV-1 disease. Lancet, The, 2000, 355, 599-604.	6.3	94
4	Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5318-5323.	3.3	92
5	Quantitation of Human Immunodeficiency Virus Type 1 DNA Forms with the Second Template Switch in Peripheral Blood Cells Predicts Disease Progression Independently of Plasma RNA Load. Journal of Virology, 2002, 76, 10099-10108.	1.5	84
6	Tracing day-zero and forecasting the COVID-19 outbreak in Lombardy, Italy: A compartmental modelling and numerical optimization approach. PLoS ONE, 2020, 15, e0240649.	1.1	52
7	A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiology and Infection, 2009, 137, 961-969.	1.0	50
8	Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. Aids, 2004, 18, 2261-2267.	1.0	44
9	Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness Loss. PLoS Pathogens, 2007, 3, e79.	2.1	43
10	Low-Dose IFN- $\beta$ Monotherapy in Treatment-Naive Individuals with HIV-1 Infection: Evidence of Potent Suppression of Viral Replication. Journal of Interferon and Cytokine Research, 2001, 21, 861-869.	0.5	41
11	European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus. Journal of Clinical Virology, 2006, 36, 111-118.	1.6	40
12	Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines. Vaccine, 2022, 40, 183-186.	1.7	40
13	Modeling the 2014 Ebola Virus Epidemic 2013 Agent-Based Simulations, Temporal Analysis and Future Predictions for Liberia and Sierra Leone. PLOS Currents, 2015, 7, .	1.4	37
14	Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: Comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays: LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. Journal of Virological Methods, 2006, 131, 168-174.	1.0	36
15	The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism. Vaccine, 2021, 39, 4925-4927.	1.7	35
16	Caenorhabditis elegans-based Model Systems for Antifungal Drug Discovery. Current Pharmaceutical Design, 2011, 17, 1225-1233.	0.9	33
17	Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study. Vaccine, 2021, 39, 2605-2607.	1.7	33
18	The Impact of Human Allelic Variation on HIV-1 Disease. Current HIV Research, 2003, 1, 185-203.	0.2	30

#	ARTICLE	IF	CITATIONS
19	The Role of <i>Candida albicans</i> SPT20 in Filamentation, Biofilm Formation and Pathogenesis. PLoS ONE, 2014, 9, e94468.	1.1	27
20	A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States. Vaccine, 2021, 39, 6585-6590.	1.7	26
21	Comparative hepatitis A seroepidemiology in 10 European countries. Epidemiology and Infection, 2012, 140, 2172-2181.	1.0	25
22	Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods. PLoS ONE, 2022, 17, e0266958.	1.1	25
23	Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma. Journal of Virological Methods, 2001, 91, 67-74.	1.0	19
24	A bulletin from Greece: a health system under the pressure of the second COVID-19 wave. Pathogens and Global Health, 2021, 115, 133-134.	1.0	18
25	SARS-CoV-2 transmission, the ambiguous role of children and considerations for the reopening of schools in the fall. Future Microbiology, 2020, 15, 1201-1206.	1.0	17
26	Global Genetic Variation of HIV-1 Infection. Current HIV Research, 2006, 4, 365-373.	0.2	14
27	Estimating seroprevalence of vaccine-preventable infections: is it worth standardizing the serological outcomes to adjust for different assays and laboratories?. Epidemiology and Infection, 2015, 143, 2269-2278.	1.0	14
28	Forecasting and control policy assessment for the Ebola virus disease (EVD) epidemic in Sierra Leone using small-world networked model simulations. BMJ Open, 2016, 6, e008649.	0.8	14
29	<i>SDH2</i> is involved in proper hypha formation and virulence in <i>Candida albicans</i> . Future Microbiology, 2018, 13, 1141-1156.	1.0	13
30	The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries. Epidemiology and Infection, 2009, 137, 485-494.	1.0	12
31	Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology, 2012, 428, 86-97.	1.1	12
32	Molecular characterization of a complex, recombinant human immunodeficiency virus type 1 (HIV-1) isolate (A/G/J/K/?): evidence to support the existence of a novel HIV-1 subtype. Journal of General Virology, 2001, 82, 2509-2514.	1.3	12
33	Molecular epidemiology of GB virus C/hepatitis G virus in Athens, Greece. Journal of Medical Virology, 2000, 61, 319-326.	2.5	11
34	Prevalence and genotypic distribution of TT virus in Athens, Greece. Journal of Medical Virology, 2001, 65, 423-429.	2.5	11
35	Environmental testing for SARS-CoV-2 in three tertiary-care hospitals during the peak of the third COVID-19 wave. American Journal of Infection Control, 2021, 49, 1435-1437.	1.1	10
36	A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021. Journal of Medical Virology, 2022, 94, 1465-1472.	2.5	10

#	ARTICLE	IF	CITATIONS
37	Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. <i>Journal of Virological Methods</i> , 2004, 121, 93-99.	1.0	9
38	The European Sero-Epidemiology Network 2: standardization of assay results for hepatitis B virus. <i>Journal of Viral Hepatitis</i> , 2007, 14, 260-268.	1.0	9
39	Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach. <i>International Journal of Cardiology</i> , 2022, 358, 136-139.	0.8	9
40	Fulminant hepatic failure in a pediatric patient with active GB virus C (GBV-C)/hepatitis G virus (HGV) infection. <i>Hepatology Research</i> , 2002, 23, 85-89.	1.8	8
41	Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020. <i>MSphere</i> , 2021, 6, e0018021.	1.3	8
42	Varicella zoster virus transmission dynamics in Vojvodina, Serbia. <i>PLoS ONE</i> , 2018, 13, e0193838.	1.1	7
43	The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape. <i>Journal of Personalized Medicine</i> , 2022, 12, 439.	1.1	6
44	Viral Correlates of HIV-1 Disease. <i>Current HIV Research</i> , 2005, 3, 113-132.	0.2	5
45	Seroepidemiology of varicella zoster virus infection in Vojvodina, Serbia. <i>Epidemiology and Infection</i> , 2018, 146, 1593-1601.	1.0	5
46	Toward High-Throughput Fungal Electroculturomics and New Omics Methodologies in 21st-Century Microbiology and Ecology. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 493-504.	1.0	5
47	Lessons from the devastating impact of the first COVID-19 wave in Italy. <i>Pathogens and Global Health</i> , 2021, 115, 211-212.	1.0	5
48	Comparative assessment of allergic reactions to COVID-19 vaccines in Europe and the United States. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1630-1633.	2.7	5
49	Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States. <i>Expert Review of Vaccines</i> , 2022, 21, 1691-1696.	2.0	5
50	Glimpses into evolutionary trajectories of SARS-CoV-2: emerging variants and potential immune evasion routes. <i>Future Microbiology</i> , 2021, 16, 455-459.	1.0	3
51	Genetic Evolution of Human Immunodeficiency Virus Type 1 in Two Spouses Responding Successfully to Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 65-71.	0.5	2
52	Declining seroprevalence of hepatitis A in Vojvodina, Serbia. <i>PLoS ONE</i> , 2019, 14, e0217176.	1.1	2
53	Pixel-Based Machine Learning and Image Reconstitution for Dot-ELISA Pathogen Diagnosis in Biological Samples. <i>Frontiers in Microbiology</i> , 2021, 12, 562199.	1.5	2
54	Estimation of the age-specific per-contact probability of Ebola virus transmission in Liberia using agent-based simulations. <i>AIP Conference Proceedings</i> , 2016, , .	0.3	0

#	ARTICLE	IF	CITATIONS
55	Data-based analysis, modelling and forecasting of the COVID-19 outbreak. , 2020, 15, e0230405.		0
56	Data-based analysis, modelling and forecasting of the COVID-19 outbreak. , 2020, 15, e0230405.		0
57	Data-based analysis, modelling and forecasting of the COVID-19 outbreak. , 2020, 15, e0230405.		0
58	Data-based analysis, modelling and forecasting of the COVID-19 outbreak. , 2020, 15, e0230405.		0